> ## Content Index
> Fetch the complete content index at: https://thecrimsonhub.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oversight, Shmoversight: Big Pharma Dodges Suggested Scrutiny in Lefty Groundwork Collaborative “Oversight” Memo
- URL: https://thecrimsonhub.com/oversight-shmoversight-big-pharma-dodges-suggested-scrutiny-in-lefty-groundwork-collaborative-oversight-memo/
- Published: 2026-11-18T17:01:00.000Z
- Updated: 2026-11-18T18:24:54.000Z
- Author: Caleb Howe

Earlier today, [Crimson Hub published the “confidential” 182-page memo](https://thecrimsonhub.com/read-it-here-first-the-sanders-warren-hit-list-of-probable-subpoena-targets-in-the-the-congress/) prepared by former Bernie Sanders and Elizabeth Warren staffers at the progressive Groundwork Collaborative.

The memo is a veritable who’s who of big names in corporate America, all of whom Sanders, Warren, and the DSA contingent want to rake over the coals over alleged “corruption,” which mostly means prices Democrats regard as “too high” and business practices they dislike, in part because labor unions dislike them.

Call it the DSA corporate “hit list”—replete with many of the names you might expect.

But for all that the memo looks like a guide to attacking big companies, it’s notable for the corporate behemoths it leaves off. Some companies broadly reviled by Americans apparently don’t merit attention, if you’re a Sanders-Warren acolyte.

Among those who dodged the proverbial Groundwork Collaborative bullet?

**Big Pharma companies.**

💡

The pharma target list in the memo is just two drug companies, Eli Lilly and Johnson & Johnson.

While the document indicates a general progressive-to-socialist desire to hit grocery companies, airlines, tech companies, insurers, and especially companies associated with the Trump family, Elon Musk, and the Ellison family hard, pharma companies looking to squeeze rural hospitals have broadly dodged scrutiny.

The pharma target list in the memo is just two drug companies, Eli Lilly and Johnson & Johnson.

The other three listed under the “Pharma” section are not pharma companies at all; they are pharmacy benefit managers.

Neither Lilly nor Johnson & Johnson are among the ten pharma companies that have received approval from the Health Resources and Services Administration (HRSA) to participate in a controversial change to the 340B drug pricing program, which overwhelmingly benefits hospitals serving Americans in red, working class, rural areas—i.e., Republicans.

## Sign up for The Crimson Hub

News, Analysis, Politics, Media, Sports

Subscribe 

Email sent! Check your inbox to complete your signup. 

No spam. Unsubscribe anytime.

Among those drugmakers are AbbVie, Amgen, AstraZeneca, Merck, Pfizer, and Bristol Myers Squibb.

None of the ten made the Democrats’ proposed pharma hit list, despite pushing for a change that would be the functional equivalent of banning you or me from using coupons when doing our grocery shopping, and requiring us to submit reams of Excel spreadsheets after doing our shopping every week to maybe, possibly get money back from the grocery store, if the store likes the way we filled out the relevant forms.

Not only do hospitals credibly argue that’s a perversion of the program’s legal requirements—it allows qualifying hospitals to purchase certain prescription drugs at a discount. It’s also a policy change that would enable pharma companies to bank much richer profits, and according to [one Wall Street analyst](https://247wallst.com/health-and-healthcare/2026/10/21/changes-to-this-100-billion-federal-drug-program-could-make-banks-the-hidden-beneficiaries/?ref=thecrimsonhub.com), potentially even function to boost the profits of big Wall Street banks. All while risking more rural hospital closures and/or a [$500 billion taxpayer-funded bailout](https://www.washingtonexaminer.com/restoring-america/faith-freedom-self-reliance/4530848/340b-keeps-rural-hospitals-alive/?ref=thecrimsonhub.com).

Ironically, the Groundwork memo singles out Johnson & Johnson for attempting to substitute upfront 340B discounts with rebates—so they’re not unaware of the problem.

However, Groundwork’s focus appears to narrowly focus on companies that cut well-publicized deals with President Trump for his Trump Rx program. That should raise suspicion that the Groundwork “hit list” is less about oversight of those trying to drive costs up and/or mess up US health care, and more about partisan progressives pushing a much more narrow anti-Trump agenda.

It’s worth noting this wouldn’t be the first time that Sanders and Sanders-linked individuals have been tagged with overlooking the importance of these discounts, and how big drugmakers are trying to evade them.

Sanders has long prioritized health care clinics in Vermont, while picking fights with hospitals. Players in the pharma industry, meanwhile, have recently [tag-teamed](https://www.asap340b.org/?ref=thecrimsonhub.com) with clinics like those Sanders backs to gut 340B for all but the clinics directly. Other Vermont liberals have gotten in on this act, including famed “Dean Scream” screamer Howard Dean.

On the plus side, Sen. Josh Hawley, who has a deeper understanding of these issues and less bias against hospitals, is likely to remain on the Senate Health, Education, Labor and Pensions (HELP) Committee that Sanders is expected to chair, and from which he will conduct “oversight” and “investigations” in line with Groundwork’s suggestions.

Perhaps he can get the work done that the Groundwork memo’s pretext suggests should be accomplished, instead of dabbling in DSA-geared theatrics that ignore the needs of a solid 30 to 50 percent of the country.